Olivier Nataf

Olivier Nataf has over 20 years of experience in the pharmaceutical industry. In 2001, he joined AstraZeneca, where he held various international leadership positions in oncology. He led drug launches in immuno-oncology and precision medicine in the United States, France, and emerging markets. In 2017, he was appointed Head of Oncology in the United States, and in 2019, he became President of AstraZeneca’s French subsidiary, strengthening the company’s position in the French market. He also serves on the board of directors of Leem.

Since 2023, Olivier has been the Global Head of the Oncology at Sanofi. He leads the development of a strategic pipeline of cancer treatments, overseeing a multidisciplinary team and collaborating with R&D teams on innovative technologies. Under his leadership, Sanofi has reinforced its commitment to oncology, adopting a patient-centered vision and leveraging strategic partnerships, such as the one with Orano Med.

He holds a degree in molecular biology from Pierre and Marie Curie University and the University of Chicago. He also earned a DEA in pharmaco-oncology from the École Normale Supérieure in Paris and a Master degree in medical management from ESCP.